Show simple item record

dc.contributor.authorGündüz, Şeyda Gülenay
dc.contributor.authorMutlu, Hasan
dc.contributor.authorTural, Deniz
dc.contributor.authorYıldız, Özcan
dc.contributor.authorUysal, Mükremin
dc.contributor.authorÇoşkun, Hasan Şenol
dc.contributor.authorBozcuk, Hakan Şat
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:36:37Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:36:37Z
dc.date.issued2015en_US
dc.identifier.citationGündüz, Ş. G., Mutlu, H., Tural, D., Yıldız, Ö., Uysal, M., Çoşkun, H. Ş. ... Bozcuk, H. Ş. (2015). Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer. Asia-Pacific Journal of Clinical Oncology, 11(4), 288-292. https://dx.doi.org/10.1111/ajco.12358en_US
dc.identifier.issn1743-7555
dc.identifier.issn1743-7563
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1212
dc.identifier.urihttps://dx.doi.org/10.1111/ajco.12358
dc.description.abstractAim: The objective of this study was to evaluate the blood platelet-lymphocyte ratio (PLR) for its prognostic value in patients with metastatic renal cell cancer (RCC). Methods: We retrospectively reviewed 100 patients diagnosed with metastatic RCC previously treated with tyrosine kinase inhibitors from three centers. We assessed the prognostic value of pretreatment PLR and other clinical and laboratory parameters based on univariate and multivariate analyses. Results: Median progression-free survival (PFS) was 7.3 months and median overall survival (OS) was 15.3 months. Multivariate analysis revealed that PFS is significantly affected by ECOG PS (P=0.047), PLR (P=0.029) and calcium level (P=0.023). Median PFS was 13.9 versus 5.3 months in patients with PLR?210 versus PLR>210 (log rank; P=0.001). Median OS was 25.9 versus 10.9 months with PLR?210 versus PLR>210 (log rank; P=0.013). Conclusions: This study shows that increased pretreatment PLR is an independent prognostic indicator in patients with metastatic RCC who use tyrosine kinase inhibitors.en_US
dc.language.isoengen_US
dc.publisherWiley-Blackwellen_US
dc.rightsinfo:eu-repo/semantics/embargoedAccessen_US
dc.subjectMetastatic Renal Cell Carcinomaen_US
dc.subjectPlatelet to Lymphocyte Ratioen_US
dc.subjectPrognosisen_US
dc.titlePlatelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell canceren_US
dc.typearticleen_US
dc.relation.journalAsia-Pacific Journal of Clinical Oncologyen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume11en_US
dc.identifier.issue4en_US
dc.identifier.startpage288en_US
dc.identifier.endpage292en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.1111/ajco.12358en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record